STOCK TITAN

Journey Medical Corporation - DERM STOCK NEWS

Welcome to our dedicated page for Journey Medical Corporation news (Ticker: DERM), a resource for investors and traders seeking the latest updates and insights on Journey Medical Corporation stock.

Journey Medical Corporation (symbol: DERM) is a commercial stage pharmaceutical company dedicated to the development and commercialization of products designed to treat dermatological conditions. With a diverse portfolio that includes eight branded and three authorized generic prescription drugs marketed in the United States, Journey Medical is committed to improving the quality of life for patients with skin conditions.

Among the well-known products in their lineup are Qbrexza, a topical treatment for excessive underarm sweating, Accutane, a potent medication for severe acne, Amzeeq, a foam treatment for acne vulgaris, and Exelderm, an antifungal solution. These products highlight the company's dedication to addressing various dermatological needs.

Recently, Journey Medical secured additional capital to support general corporate purposes, including funding for the potential launch of DFD-29. This demonstrates their strategic effort to expand their product offerings and enhance their market presence.

The company is proactive in maintaining transparent communication with its stakeholders. They have scheduled a conference call on March 21, 2024, to discuss financial results and provide a corporate update. Furthermore, another conference call is set for May 13, 2024.

Looking ahead, an important milestone for Journey Medical is the Prescription Drug User Fee Act (PDUFA) goal date on November 4, 2024. This date is crucial for the approval process of their new drug applications, reflecting the company's ongoing efforts in drug development and commercialization.

For more information, investors and interested parties can contact Jaclyn Jaffe at (781) 652-4500 or via email at ir@jmcderm.com. Media inquiries can be directed to Tony Plohoros at (908) 591-2839 or tplohoros@6degreespr.com.

Rhea-AI Summary
Journey Medical Corporation (Nasdaq: DERM) announced a credit facility with SWK Holdings Corporation for up to $20 million to support general corporate purposes and potential launch of DFD-29.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.29%
Tags
none
-
Rhea-AI Summary
Journey Medical Corporation (Nasdaq: DERM) is on track to submit a New Drug Application to the FDA for DFD-29 around year-end of 2023. Positive topline data from Journey Medical’s two DFD-29 Phase 3 clinical trials for the treatment of rosacea were reported in July 2023, achieving all co-primary and secondary endpoints with no significant safety issues.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.1%
Tags
none
-
Rhea-AI Summary
DERM: Journey Medical Corporation Announces 101% Increase in Net Revenues to $34.5 Million in Q3 2023, GAAP Net Income of $16.8 Million, and Exclusive License Agreement with Maruho Co., Ltd.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.62%
Tags
Rhea-AI Summary
Journey Medical Corporation will release its third quarter 2023 financial results on November 7, 2023. The company will host a conference call and audio webcast at 4:30 p.m. ET on the same day. Interested parties can join the call by dialing 1-866-777-2509 (domestic) or 1-412-317-5413 (international). A live audio webcast will also be available on Journey Medical's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.94%
Tags
-
Rhea-AI Summary
Journey Medical announces data from a comparative bioavailability study of DFD-29 vs. Solodyn for the treatment of rosacea
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.33%
Tags
none
-
Rhea-AI Summary
Journey Medical enters exclusive license agreement with Maruho Co., Ltd. for Qbrexza in multiple territories
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.68%
Tags
none
Rhea-AI Summary
Journey Medical Corporation (Nasdaq: DERM) announced a 41% increase in total net revenues to $17.2 million in Q2 2023, and positive topline results from two Phase 3 clinical trials evaluating DFD-29 for papulopustular rosacea treatment. The company plans to submit an NDA to the FDA for DFD-29 in H2 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
-
Rhea-AI Summary
DERM: Journey Medical Corporation to Discuss Positive Topline Clinical Data and Financial Results in Upcoming Conference Call on August 8, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.01%
Tags
-
Rhea-AI Summary
Journey Medical Corporation will release its second quarter 2023 financial results during the week of August 7, 2023. The company will also host a conference call to discuss the results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags

FAQ

What is the current stock price of Journey Medical Corporation (DERM)?

The current stock price of Journey Medical Corporation (DERM) is $4.68 as of December 20, 2024.

What is the market cap of Journey Medical Corporation (DERM)?

The market cap of Journey Medical Corporation (DERM) is approximately 96.1M.

What does Journey Medical Corporation do?

Journey Medical Corporation develops and commercializes pharmaceutical products for dermatological conditions.

What are some of Journey Medical's key products?

Key products include Qbrexza, Accutane, Amzeeq, Exelderm, and several others targeting skin conditions.

What recent achievements has Journey Medical Corporation made?

Journey Medical recently secured additional capital to support the potential launch of DFD-29 and other corporate purposes.

When is the next conference call for Journey Medical?

The next conference call is scheduled for March 21, 2024, followed by another on May 13, 2024, both at 4:30 p.m. ET.

What is the PDUFA goal date for Journey Medical?

The PDUFA goal date for their new drug applications is November 4, 2024.

How can I contact Journey Medical for investor relations?

You can contact Jaclyn Jaffe at (781) 652-4500 or via email at ir@jmcderm.com.

Who handles media relations for Journey Medical?

Tony Plohoros handles media relations and can be contacted at (908) 591-2839 or at tplohoros@6degreespr.com.

What is DFD-29?

DFD-29 is a potential new product in Journey Medical's pipeline for which they have secured funding for development.

Where are Journey Medical's products marketed?

Journey Medical's products are marketed in the United States.

What is the focus of Journey Medical Corporation?

The company focuses on developing and commercializing treatments for dermatological conditions.

Journey Medical Corporation

Nasdaq:DERM

DERM Rankings

DERM Stock Data

96.09M
16.35M
30.48%
24.86%
0.32%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
SCOTTSDALE